Associated Banc Corp Raises Stock Holdings in IQVIA Holdings Inc. $IQV

Associated Banc Corp grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 181,003 shares of the medical research company’s stock after buying an additional 4,840 shares during the period. Associated Banc Corp’s holdings in IQVIA were worth $30,868,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of IQV. ARQ Wealth Advisors LLC purchased a new position in IQVIA during the 1st quarter valued at about $224,000. SFE Investment Counsel grew its holdings in IQVIA by 8.1% in the first quarter. SFE Investment Counsel now owns 51,922 shares of the medical research company’s stock worth $8,855,000 after purchasing an additional 3,903 shares during the period. Fifth Third Bancorp increased its stake in shares of IQVIA by 248.4% during the first quarter. Fifth Third Bancorp now owns 78,755 shares of the medical research company’s stock valued at $13,431,000 after purchasing an additional 56,151 shares in the last quarter. WealthShield Partners LLC bought a new stake in shares of IQVIA in the 1st quarter worth approximately $1,741,000. Finally, Sequoia Financial Advisors LLC grew its stake in shares of IQVIA by 16.9% in the 1st quarter. Sequoia Financial Advisors LLC now owns 9,811 shares of the medical research company’s stock worth $1,673,000 after buying an additional 1,421 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

Shares of IQV traded down $0.84 during mid-day trading on Friday, hitting $208.13. 747,394 shares of the company traded hands, compared to its average volume of 1,464,238. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a 50-day moving average price of $181.62 and a two-hundred day moving average price of $188.78. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $247.04. The stock has a market cap of $34.74 billion, a price-to-earnings ratio of 25.79, a P/E/G ratio of 1.78 and a beta of 1.20.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has authorized a stock buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IQV shares. HSBC reiterated a “buy” rating and set a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Evercore reaffirmed an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Weiss Ratings lowered shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Finally, Robert W. Baird upped their target price on shares of IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 1st. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $224.82.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.